Point72 Hong Kong Ltd Has $258,000 Stock Holdings in Eli Lilly And Co (NYSE:LLY)
Point72 Hong Kong Ltd trimmed its position in shares of Eli Lilly And Co (NYSE:LLY) by 71.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,962 shares of the company’s stock after selling 4,864 shares during the quarter. Point72 Hong Kong Ltd’s holdings in Eli Lilly And Co were worth $258,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Pacitti Group Inc. acquired a new position in Eli Lilly And Co in the fourth quarter valued at about $25,000. Sugarloaf Wealth Management LLC bought a new position in shares of Eli Lilly And Co during the 4th quarter valued at about $26,000. Solstein Capital LLC bought a new position in shares of Eli Lilly And Co during the 4th quarter valued at about $34,000. Capital Wealth Alliance LLC acquired a new position in shares of Eli Lilly And Co in the 4th quarter valued at approximately $34,000. Finally, Retirement Network acquired a new position in shares of Eli Lilly And Co in the 4th quarter valued at approximately $38,000. 77.83% of the stock is currently owned by institutional investors.
Several brokerages have commented on LLY. Mizuho started coverage on shares of Eli Lilly And Co in a report on Wednesday, February 5th. They set a “neutral” rating and a $148.00 target price on the stock. Argus upped their price target on shares of Eli Lilly And Co from $145.00 to $165.00 and gave the company a “buy” rating in a report on Monday, December 30th. Goldman Sachs Group upgraded shares of Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 price objective on the stock in a report on Wednesday, March 11th. Barclays began coverage on shares of Eli Lilly And Co in a report on Thursday, February 27th. They set an “overweight” rating on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly And Co from $140.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $142.18.
Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Thursday, January 30th. The company reported $1.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.52 by $0.21. The business had revenue of $6.11 billion during the quarter, compared to analysts’ expectations of $5.92 billion. Eli Lilly And Co had a net margin of 37.27% and a return on equity of 192.27%. The firm’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.33 earnings per share. On average, analysts anticipate that Eli Lilly And Co will post 6.77 earnings per share for the current year.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 9th. The stock was sold at an average price of $135.79, for a total value of $29,873,800.00. Following the completion of the transaction, the insider now directly owns 114,136,224 shares in the company, valued at $15,498,557,856.96. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Myles O’neill sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $140.15, for a total value of $3,503,750.00. Following the completion of the transaction, the senior vice president now owns 44,773 shares of the company’s stock, valued at $6,274,935.95. The disclosure for this sale can be found here. Insiders have sold a total of 682,645 shares of company stock worth $95,516,671 over the last three months. Insiders own 0.11% of the company’s stock.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: What are defining characteristics of a correction?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.